跳轉至內容
Merck
全部照片(1)

重要文件

檢視所有文件

P8828

Sigma-Aldrich

培高利特 甲磺酸盐

≥98%, solid

同義詞:

8β-[(Methylthio)methyl]-6-propylergoline methanesulfonate salt, Pergolide methanesulfonate salt

登入查看組織和合約定價
全部照片(1)

About This Item

經驗公式（希爾表示法）:
C19H26N2S · CH4O3S
CAS號碼:
66104-23-2
分子量：:
410.59
MDL號碼:
MFCD00153859
分類程式碼代碼:
12352200
PubChem物質ID:
24277927
NACRES:
NA.77
暫時無法取得訂價和供貨情況

化驗

≥98%

形狀

solid

光學活性

[α]20/D −35°, c = 0.2 in pyridine(lit.)

顏色

white

溶解度

ethanol: 2 mg/mL
DMSO: 5.2 mg/mL
H2O: insoluble

起源

Valeant

儲存溫度

−20°C

SMILES 字串

CS(O)(=O)=O.[H][C@@]12Cc3c[nH]c4cccc(c34)[C@@]1([H])C[C@@H](CSC)CN2CCC

InChI

1S/C19H26N2S.CH4O3S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21;1-5(2,3)4/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3;1H3,(H,2,3,4)/t13-,16-,18-;/m1./s1

InChI 密鑰

UWCVGPLTGZWHGS-ZORIOUSZSA-N

基因資訊

human ... DRD1(1812) , DRD2(1813) , DRD3(1814) , DRD4(1815) , DRD5(1816)

尋找類似的產品？ 前往 產品比較指南

生化／生理作用

Dopaminergic agonist; suppresses pituitary secretion of prolactin; anti-Parkinsonian agent.

特點和優勢

This compound was developed by Valeant. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

象形圖

Skull and crossbones
GHS06

訊號詞

Danger

危險聲明

H300

防範說明

P264 - P301 + P310

危險分類

Acute Tox. 2 Oral

儲存類別代碼

6.1B - Non-combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

個人防護裝備

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

從最近期的版本中選擇一個：

分析證明 (COA)

Lot/Batch Number
SLBM6092V
SLBF6838V
070M2011V
070M2011
119K1638

未看到正確版本？

如果您需要一個特定的版本，您可以透過批號來尋找特定憑證。

搜尋 COA

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Richard P Allen et al.
Sleep medicine, 12(5), 431-439 (2011-04-16)
Assess the rate of augmentation as it occurs during standard long-term dopaminergic treatment of RLS, potential risk factors or predictors of augmentation, the relationship between treatment duration and augmentation, and the clinical impact of augmentation on subjects' health outcomes. Two
Marie Innerå et al.
Veterinary dermatology, 24(1), 212-217 (2013-01-22)
Pituitary pars intermedia dysfunction (PPID) in older equids is commonly recognized by a long hair coat that fails to shed. The aim of this study was to compare hair follicle stages in PPID-affected horses with excessively long hair coats with
P Barone et al.
Neurology, 53(3), 573-579 (1999-08-17)
To determine whether pergolide monotherapy provides symptomatic relief in early PD. Early treatment with dopamine agonists may reduce the risk of motor fluctuations, which are most likely linked to levodopa therapy. Pergolide, a D1-D2 dopamine agonist, has been studied as
Hanna Scholz et al.
The Cochrane database of systematic reviews, (3)(3), CD006009-CD006009 (2011-03-18)
According to clinical guidelines, dopamine agonists are the first-line treatment of restless legs syndrome (RLS). To evaluate efficacy and safety of dopamine agonists for RLS. We searched the Cochrane Central Register of Controlled Trials (The Cochrane Library 2008, Issue 4)
Alin Ciobica et al.
Journal of physiology and biochemistry, 68(1), 59-69 (2011-10-19)
One of the most widely used animal models of Parkinson's disease (PD) involves injecting 6-hydroxydopamine (6-OHDA) directly into the substantia nigra (SN). Some recent reports speculated that dopaminergic drugs may exert brain antioxidant activity, which could explain some of their
查看所有相關論文

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務